China Clinical Data Crackdown Sees Device-Makers Withdraw 101 Applications
Executive Summary
China FDA is now relentlessly clamping down on clinical data irregularities in the medtech industry, causing 51 manufacturers, including well-known multinational companies such as Boston Scientific and Olympus, to withdraw more than a hundred new device approvals filed with the agency.
You may also be interested in...
China Proposes Stricter Rules And Higher Penalties For Recalls
The China Food and Drug Administration wants to expand the scope of products subject to recall and increase the penalties for wrongdoers.
China Plan To Exempt More Devices From Trials To Save Time, Costs
China's Food and Drug Administration invited feedback on a new batch of medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.